Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 162Carcinoma, Non-Small-Cell Lung 109Lung Neoplasms 54Hodgkin Disease 22Neoplasm Metastasis 16Recurrence 15Lymphoma 15Neoplasms 14Triple Negative Breast Neoplasms 13Prostatic Neoplasms 10Adenocarcinoma of Lung 10Sarcoma 9Rhabdomyosarcoma 9Uterine Cervical Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 6Ovarian Neoplasms 5Mesothelioma, Malignant 5Breast Neoplasms, Male 5Small Cell Lung Carcinoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4NSCLC 4Multiple Myeloma 4Brain Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Vinorelbine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pathologic Residual Cancer Cells × Vinorelbine × Clear all
NCT03703427 2018-10-12

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Shandong Cancer Hospital and Institute

Phase 2 Unknown
200 enrolled

Pathologic Residual Cancer Cells

Data powered by HemOnc (CC BY 4.0) Colophon âš¡